To Our Shareholders
and Investors

• November 14, 2025

  Management & Finance
  Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2025
• October 30, 2025

  R & D
  Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults
• October 14, 2025

  R & D
  Brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy: 3.5-Year Clinical Trial Data Presented at the World Muscle Society 2025 Congress
• October 02, 2025

  R & D
  Brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne Muscular Dystrophy: Presenting 3.5-Year Clinical Trial Data at the World Muscle Society 2025 Congress

Upcoming Events

• November 14, 2025
  IR Meeting(Q2/FY2025)
• November 14, 2025
  FY2025 2nd Qtr results announcement
• August 07, 2025
  Conference Call(Q1/FY2025)
• August 07, 2025
  FY2025 1st Qtr results announcement
• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1.0 MB